login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMAGO BIOSCIENCES INC (IMGO) Stock News
USA
-
Nasdaq
- NASDAQ:IMGO -
US45250K1079
-
Common Stock
36.01
USD
+0.01 (+0.03%)
Last: 1/10/2023, 8:15:28 PM
36.01
USD
0 (0%)
After Hours:
1/10/2023, 8:15:28 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMGO Latest News, Press Relases and Analysis
All
Press Releases
3 years ago - By: InvestorPlace
- Mentions:
MCK
MRK
UNH
VIR
...
7 Healthcare Stocks That Will Be Big Winners in 2023
3 years ago - By: InvestorPlace
- Mentions:
MRK
LLY
REGN
AMGN
...
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
3 years ago - By: Benzinga
Looking Into Imago BioSciences's Recent Short Interest
3 years ago - By: Benzinga
- Mentions:
HZNP
VKTX
CBAY
MDGL
5 Most Expensive Health Care Stocks You Should Worry About
3 years ago - By: Seeking Alpha
- Mentions:
MRK
SGEN
Merck is best performing large U.S. pharma of 2022 (NYSE:MRK)
3 years ago - By: Imago Biosciences, Inc.
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
3 years ago - By: Imago Biosciences, Inc.
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
3 years ago - By: Imago Biosciences, Inc.
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
3 years ago - By: Merck & Co., Inc.
- Mentions:
MRK
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
3 years ago - By: Imago Biosciences, Inc.
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
3 years ago - By: InvestorPlace
- Mentions:
AAPL
HD
MRK
OXY
...
3 Dow Stocks to Take Seriously in 2023
3 years ago - By: Kahn Swick & Foti, LLC
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO
3 years ago - By: Weiss Law
- Mentions:
MRK
SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.
3 years ago - By: Ademi LLP
Shareholder Alert: Ademi LLP investigates whether Imago BioSciences, Inc. has obtained a Fair Price in its transaction with Merck
Please enable JavaScript to continue using this application.